Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Myelodysplastic Syndromes
•
Hematology
Would you hold off iron chelation in a transfusion dependent MDS patient with elevated ferritin but with negative iron stain on the bone marrow?
Are there other investigations you would pursue to guide decision?
Related Questions
How do you approach severe anemia and thrombocytopenia in an elderly patient whose bone marrow biopsy shows hypercellular marrow with mild dysplasia in erythroid and megakaryocytic lineage but normal cytogenetics and a negative NGS panel?
What is your approach for choosing between Imetelstat and Luspatercept in managing MDS related anemia?
How do you manage high-risk MDS IB2 patients on HMA and venetoclax who develop an acute stroke requiring antiplatelet therapy?
How do you manage a patient with low risk MDS who achieves transfusion independence with luspatercept but continues to have fatigue?
How do you approach management for CCUS with severe cytopenias?
How do you sequence luspatercept and imetelstat for treatment of anemia in MDS?
How do you time CSF analysis for suspected CNS lymphoma in patients who are on steroids?
What is your approach to managing follicular lymphoma with central nervous system involvement?
What factors should be considered when deciding whether to omit radiation in pediatric/AYA patients receiving N+AVD, particularly regarding long-term outcomes and second malignancy risks?
How would you approach a young, fit patient with suspected CNS involvement with high circulating blasts?